ClinicalTrials.gg
RecruitingNCT07644039Updated Oct 13, 2026

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

A Phase 1/2 interventional study of Pembrolizumab and PM54 in Advanced Malignancies, sponsored by PharmaMar. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by PharmaMar · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 13, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed and dated written , obtained before the start of any study-specific procedures.
  2. Adults (greater than or equal to [>=]18 years or legal consenting age, per local regulations), and able to provide free and informed consent for study participation.
  3. Have a confirmed diagnosis of advanced .
  4. Have advanced disease, as defined by progressive, , or disease that is not amenable to multimodal ablative or excisional treatments with curative intent, according to international guidelines.
  5. Have according to RECIST1.1 (or v1.1 where applicable).
  6. Have experienced objective disease progression on or following the prior line(s) of systemic therapy, as determined either by (1) v1.1 or equivalent, or (2) by investigator's assessment of clinical progression of disease together with objective evidence of increased tumor burden even if not meeting criteria for progressive disease per RECIST v1.1 or equivalent.
  7. (ECOG) Performance Status (PS) of 0 or 1 at screening.
  8. Individuals with central nervous system (CNS) metastases are eligible, as long as all of the following are met:

    1. Asymptomatic or minimally symptomatic and stable, with no worsening symptoms in the 4 weeks prior to start of study intervention.
    2. Does not require systemic in excess of an equivalent prednisone dose of 5 milligrams per day (mg/day).
    3. Has undergone surgery or radiation and recovered of the effects thereof or are undergoing active surveillance for small-volume with no immediate risk of worsening. A minimum of 2 weeks must have elapsed between the end of whole-brain radiation treatment and study intervention.
    4. Have not had an epileptic seizure within the 4 weeks prior to start of anticancer treatment and are either free of antiepileptics or on a stable dose prescribed as prophylaxis.
  9. Adequate laboratory parameters, as specified below, within 7 days of start of study intervention:

    1. (ANC) >=1.5*10\^9 per liter, count >=100*10\^9 per liter, and >=9 gram per deciliter (g/dL).
    2. (AST) and alanine aminotransferase (ALT) less than or equal to [\<=] 3.0*the (ULN).
    3. Total \<=1.0*ULN; up to 1.5*ULN for participants with Gilbert's syndrome.
    4. >=30 milliliter per minute (mL/min), calculated using the Cockcroft and Gault's formula.
    5. Serum albumin >=3 g/dL. Albumin infusion to increase the blood level in order to fulfill this inclusion criterion is strictly forbidden.
    6. Creatine kinase \<=2.5*ULN.
  10. Recovered from the effects of any prior surgery or radiation.
  11. No ongoing toxicities from prior anticancer treatment of Grade >1 (per National Cancer Institute (NCI)- (CTCAE) verison6.0), except for alopecia and other Grade 2 toxicities that are considered by the investigator to have stabilized/resolved with sequelae and are not at risk of worsening with study intervention. Residual Grade 1 to 2 toxicities from prior immunotherapy -which may include hypo- or hyperthyroidism, type 1 diabetes, hyperglycemia, and adrenal insufficiency - are allowed, if stable and on a stable dose of replacement therapy as applicable.
  12. Is willing to undergo trial procedures as specified in the protocol, including provision of biologic samples, as well as any study restrictions.
  13. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure during the course of the trial and up to 7 months after the last study intervention infusion. Fertile male participants with WOCBP partners should use condoms during treatment and for 4 months following the last study intervention infusion.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with PM54 or any other ecteinascidin agent, including ecubectedin, trabectedin, and lurbinectedin.
  2. History of to PM54, pembrolizumab, or any of the inactive ingredients.
  3. History of other within 3 years prior to start of study intervention, except adequately resected non-melanoma skin cancer or other in-situ disease at neglectable risk of relapse.
  4. Presence of carcinomatous meningitis.
  5. Presence of any of these medical conditions

    Cardiovascular:

    1. History of myocardial, CNS, or other arterial infarction within 6 months before the start of study intervention.
    2. Heart failure Class II or higher according to the or \<45 percent (%) per echocardiogram or multigated acquisition scan.
    3. Symptomatic arrhythmia or other significant (ECG) abnormalities that in the opinion of the investigator pose an increased risk of complications.
    4. interval (QTc) >470 milliseconds (ms) on the screening ECG or history of a long QT syndrome.

      Respiratory

    5. History of interstitial lung disease (ILD) or pneumonitis that have required or other forms of , or any ongoing or suspicion of ILD.
    6. Severe underlying lung disorder, as per investigator's assessment that can include but not restricted to , asthma, restrictive lung disease, or significant pleural effusions not related to the study condition.
    7. New onset or worsening of pulmonary embolism or deep vein thrombosis within the previous 2 months, or any history thereof if no stable dose of anticoagulant regimen has been achieved.

      Other

    8. History of or connective tissue disease that (a) in the opinion of the investigator may have a significant risk of worsening with study intervention or (b) has a history or risk of significant mg/day of prednisone equivalent or other systemic immunosuppressants in the previous 1 year to control a disease flare.
    9. Uncontrolled infection requiring antimicrobial agents or unexplained fever within 3 days of the first scheduled day of dosing. Participants with tumor fever may be enrolled if infectious etiology has been adequately ruled out. j. Prior bone marrow or stem cell transplantation.
  6. Has any other medical, behavioral, or social condition that, in the opinion of the investigator, makes the participant ineligible to receive PM54, pembrolizumab, or undergo key trial procedures.
  7. Exposure to the anticancer products/treatments below, without adequate prior to first dose of study intervention. Note that hormonal therapy received for the treatment of tumors at a low risk of relapse is allowed.

    Products/treatments and washout periods:

    1. Traditional Chinese or herbal medicine with the intent to treat cancer or with known effects on drug metabolism: 28 days.
    2. Live, attenuated vaccines: 30 days.
    3. Chemotherapy: 21 days.
    4. Antibodies and antidrug conjugates: 28 days.
    5. Targeted agents and small molecules: 2 weeks or 5 half-lives, whichever is longer.
    6. Major surgery: 4 weeks. Note: Surgeries typically performed in an outpatient setting are not considered major, even if light sedation or an inpatient stay for oversight was needed.
    7. Whole-brain radiation therapy, stereotactic therapy, palliative radiation for symptom control and minor impact on bone marrow: 2 weeks.
    8. Other radiation therapy: 4 weeks.
    9. Any medication associated with increased risk of torsade de pointes, except if considered indicated by the investigator, ideally for short duration, under medical monitoring and if no other risk factors for torsade de pointes are present such as prolonged QTc or significant electrolyte abnormalities.: 5 half-lives.
    10. Strong or moderate inhibitors or inducers of cytochrome (CYP) 3A4: 2 weeks.
    11. Corticosteroids: must be \<= 10 mg/day of prednisone equivalent within 3 days of start of study intervention. The investigator is encouraged to review indication for ongoing use of corticosteroids and consider de-escalation or interruption if appropriate.
  8. Active infection. Inclusion is allowed if:

    1. Undergoing adequate anti-viral treatment and regular clinical oversight with good compliance.
    2. Undetectable human immunodeficiency virus (HIV) viral load.
    3. over 350 per millimeter cube.
    4. No evidence or suspicion of opportunistic infection. Note: The investigator should obtain and provide the sponsor with written documentation of the above, assessed by a medical doctor experienced in the management of individuals with HIV.
  9. Individuals with detectable virus (HCV) ribonucleic acid (RNA), which should be tested in case of positive anti-HCV antibody test.
  10. Positive serology test of surface antigen (HBsAg) with hepatitis B virus (HBV) DNA >= 1000 International Units per milliliter (IU/mL). Hepatitis B virus (HBV) DNA test is mandatory in case of HBsAg+. Individuals with detectable HBV DNA \<1000 IU/mL or suspected occult HBV infection must undergo prophylaxis of HBV reactivation in order to be eligible.
  11. Individuals with a short-term risk of anatomic complications from involvement of critical structures such as major vessels, large airways, and vertebral spine.
  12. Women who are pregnant or breastfeeding and fertile participants (men and women) who are not using a highly effective method of (see inclusion criterion No. 13).
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
119 participants (estimated)

Study arms

  • Experimental
    Part 1 (safety Run-in): PM54 + Pembrolizumab

    Participants will initially receive a low dose of PM54. If the low dose level is tolerated, PM54 will be escalated to the high dose level in combination with pembrolizumab until a suitable dose of PM54 is established or until clinical or objective disease progression, withdrawal of consent, or unacceptable or cumulative toxicity occurs.

    Drug: Pembrolizumab · Drug: PM54

  • Experimental
    Part 2 (Dose Expansion): PM54 + Pembrolizumab

    Participants will receive recommended dose of PM54 in combination with pembrolizumab as observed in Part 1 of the study.

    Drug: Pembrolizumab · Drug: PM54

Interventions

  • Intravenous infusion.

  • DrugPM54

    Intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Treatment Discontinuation

    Time frame: From signing of the informed consent up to 30 days after last dose (up to 3 years)

  2. Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)

    Time frame: Cycle 1 (each cycle is of 21 days)

  3. Part 2: Clinical Benefit Rate

    CBR is defined as the percentage of participants who achieve either an objective tumor response - complete response (CR), partial response (PR) - or confirmed stable disease with an absence of tumor progression during the first 12 weeks. CBR was assessed according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1. CR: Disappearance of all non-nodal target lesions and reduction in short axis of pathological lymph nodes to less than (\<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in the sum of diameters of target lesions from baseline; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progression disease (PD).

    Time frame: up to 12 weeks

  4. Part 2: Objective Response Rate

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions.

    Time frame: Baseline up to 3 years

Secondary outcomes

  1. Parts 1 and 2: Confirmed Objective Response Rate

    Confirmed ORR is defined as a best objective response (OR) of CR or PR according to mRECIST v1.1 and determined by Investigator. CR: Disappearance of all non-nodal target lesions and reduction in short axis of pathological lymph nodes to \< 10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions from baseline.

    Time frame: Baseline up to 3 years

  2. Part 1: Clinical Benefit Rate

    CBR is defined as the percentage of participants who achieve either an objective tumor response - complete response (CR), partial response (PR) - or confirmed stable disease with an absence of tumor progression during the first 12 weeks. CBR was assessed according to mRECIST v1.1 and determined by Investigator. CR: Disappearance of all non-nodal target lesions and reduction in short axis of pathological lymph nodes to less than (\<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in the sum of diameters of target lesions from baseline; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progression disease (PD).

    Time frame: up to 12 weeks

  3. Parts 1 and 2: Disease Control Rate (DCR)

    DCR defined as the percentage of participants who achieve a best overall response of CR, PR and SD according to RECIST v1.1 and determined by Investigator. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions. SD: SD: reduction in sum of diameters of target lesions of 10% or greater, confirmed on a subsequent scan.

    Time frame: Baseline up to 3 years

  4. Parts 1 and 2: Progression-free survival (PFS)

    Time frame: Baseline up to 3 years

  5. Parts 1 and 2: Duration of Response (DoR)

    Time frame: Baseline up to 3 years

  6. Parts 1 and 2: Time to Treatment Failure

    Time frame: Baseline up to 3 years

  7. Parts 1 and 2: Overall Survival (OS)

    Time frame: Baseline up to 3 years

  8. Parts 1 and 2: Percentage of Participants who Achieve a Minor Response

    Percentage of participants who achieve a minor response, defined as stable disease (per RECIST v1.1) with a reduction in sum of diameters of target lesions of 10% or greater, confirmed on a subsequent scan.

    Time frame: Baseline up to 3 years

  9. Parts 1 and 2: Plasma Concentration of PM54 and Pembrolizumab

    Time frame: Part 1- Cycle 1, Days 1 to 3: Pre-dose and at 1, 3, 6, 24 and 48 hours post-dose; Part 2- Cycle 1, Days 1 to 3: Pre-dose and at 1 and 48 hours post-dose (each cycle is 21 days)

07

Study locations

11 of 11 sites recruiting
08

References and documents

Publications

  • Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol. 2018 Jul;13(7):1012-1021. doi: 10.1016/j.jtho.2018.04.034. Epub 2018 May 9. PubMed 29753121 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Apr 2029, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
May 21, 2026
Primary completionEst.
Apr 2, 2029
CompletionEst.
Apr 2, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Institut Català d'Oncologia (ICO) - Hospital Durans i Reynals. · Barcelona, Spain
Show 1 removed
  • Institut Català d'Oncologia · Barcelona, Spain
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added, 1 site removed
    Show site
    • Institut Català d'Oncologia (ICO) - Hospital Durans i Reynals. · Barcelona, Spain
    Show 1 removed
    • Institut Català d'Oncologia · Barcelona, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07644039
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
May 21, 2026
Primary completion
Apr 2, 2029 (estimated)
Completion
Apr 2, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Cristian Fernandez, M.D.
Contact
cmfernandez@pharmamar.com
0034 91 846 6077

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion